Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01435304 · ClinicalTrials.gov registry record · NA
The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass
A NA study, sponsored by MaineHealth.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT01435304 is a NA study that has completed, run by MaineHealth. The registered enrollment target is 100 participants.
The verdict
NCT01435304, a NA study, has completed, sponsored by MaineHealth.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
This proposal is designed to mitigate hemodilution (blood diluted with an electrolyte solution) and loss of plasma proteins responsible for normal blood clotting as well as platelets at the completion of cardiopulmonary bypass (CPB). The Hemobag® system is a device qualified by the US Food and Drug Administration (FDA). Many cardiac centers, such as Englewood Hospital and Medical Center in Englewood NJ are using the Hemobag® system for Jehovah's witnesses and other patients who go to that center for bloodless cardiac surgery (cardiac surgery performed without the use of blood or blood products). The system is designed to filter excessive water from blood left in the heart lung machine (cardiopulmonary bypass) after it is separated from the patient during the performance of cardiac surgery. Consequently the likelihood of excessive post-operative bleeding and transfusion with allogeneic blood (blood bank blood from donors) is decreased.
Interventions
- DEVICE method of returning residual CPB blood ( Hemobag®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2011-09 |
| Est. Completion | 2014-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01435304
The ClinicalTrials.gov registry entry for NCT01435304 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MaineHealth, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which method of returning residual CPB blood ( Hemobag®) is the first listed.
NCT01435304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01435304 about?
NCT01435304 is a clinical study titled "The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass". This proposal is designed to mitigate hemodilution (blood diluted with an electrolyte solution) and loss of plasma proteins responsible for normal blood clotting as well as platelets at the completion of cardiopulmonary bypass (CPB). The Hemobag® system is a device qualified by the US Food and Drug ...
What is the current status of trial NCT01435304?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2011-09. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01435304?
The interventions under investigation include: method of returning residual CPB blood ( Hemobag®) (DEVICE).
Who is sponsoring clinical trial NCT01435304?
This trial is sponsored by MaineHealth, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.